Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Klaus Schomäcker"'
Autor:
Simone Wegen, Karina Claus, Philipp Linde, Johannes Rosenbrock, Maike Trommer, Thomas Zander, Armin Tuchscherer, Christiane Bruns, Hans Anton Schlößer, Wolfgang Schröder, Marie-Lisa Eich, Thomas Fischer, Klaus Schomäcker, Alexander Drzezga, Carsten Kobe, Katrin Sabine Roth, Jasmin Josefine Weindler
Publikováno v:
Radiation Oncology, Vol 19, Iss 1, Pp 1-11 (2024)
Abstract Background Fibroblast activation protein (FAP) is expressed in the tumor microenvironment (TME) of various cancers. In our analysis, we describe the impact of dual-tracer imaging with Gallium-68-radiolabeled inhibitors of FAP (FAPI-46-PET/CT
Externí odkaz:
https://doaj.org/article/ce5d14ae5759413998c9bebf6d8a92b5
Autor:
Thomas Fischer, Christopher Dietrich, Felix Dietlein, Sergio Muñoz Vázquez, Beate Zimmermanns, Philipp Krapf, Ferdinand Sudbrock, Alexander Drzezga, Markus Dietlein, Klaus Schomäcker
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 19, p 10638 (2024)
This study evaluates the efficacy of [131I]I-ERIC1 in targeting and inhibiting the growth of SCLC tumors in mice, focusing on tumor accumulation and regression and potential side effects. NCAM-positive NCI-H69 SCLC cells were implanted in CB 17 SCID
Externí odkaz:
https://doaj.org/article/c159e8a26cf847cebf574b57998110c9
Autor:
Thomas Fischer, Felix Dietlein, Detlev Bongartz, Martin Klehr, Beate Zimmermanns, Matthias Schmidt, Angela Mohr, Fabian Mohr, Ferdinand Sudbrock, Philipp Krapf, Alexander Drzezga, Markus Dietlein, Klaus Schomäcker
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 19, p 10737 (2024)
Preliminary studies on a radioactive antibody against the neural cell adhesion molecule (NCAM) demonstrated a significant accumulation of [131I]I-ERIC1 in neuroblastoma tumor cells in mice. This study aims to validate the therapeutic efficacy and pot
Externí odkaz:
https://doaj.org/article/b91729d3204143fb817347f7a35074c6
Autor:
Jan Heilinger, Jasmin Weindler, Katrin Sabine Roth, Philipp Krapf, Klaus Schomäcker, Markus Dietlein, Alexander Drzezga, Carsten Kobe
Publikováno v:
EJNMMI Research, Vol 13, Iss 1, Pp 1-11 (2023)
Abstract Background In 2022, the American Food and Drug Administration and the European Medicines Agency approved [177Lu]Lu-PSMA-617 (PLUVICTO™, Novartis AG, Basel, Switzerland) for radionuclide therapy with prostate-specific membrane antigen (PSMA
Externí odkaz:
https://doaj.org/article/638c38dfd2874b4eafd1d9ad3f555c00
Autor:
Klaus Schomäcker, Felix Dietlein, Sergio Muñoz Vázquez, Feodor Braun, Thomas Fischer, Philipp Krapf, Alexander Drzezga, Markus Dietlein
Publikováno v:
Molecules, Vol 29, Iss 1, p 185 (2023)
The interdisciplinary possibilities inherent in nuclear medicine offer an opportunity for the patient-centered development of radioactive pharmaceuticals based on specific research questions. This approach provides radiopharmaceutical manufacturers w
Externí odkaz:
https://doaj.org/article/0127700093844dd8ab1582489d9572f0
Autor:
Jochen Hammes, Melanie Hohberg, Philipp Täger, Markus Wild, Boris Zlatopolskiy, Philipp Krapf, Bernd Neumaier, Klaus Schomäcker, Carsten Kobe, Matthias Schmidt, Markus Dietlein, Alexander Drzezga
Publikováno v:
PLoS ONE, Vol 13, Iss 12, p e0209613 (2018)
INTRODUCTION:[68Ga]PSMA-HBED-CC and [18F]DCFPyL show a high potential for the detection of recurrent prostate cancer. While 18F-based tracers have several advantages in availability and image resolution, their sensitivity in the skeleton might be imp
Externí odkaz:
https://doaj.org/article/d448f68b98c84a4dafa167e89169dbfb
Autor:
Feodor Braun, Marcel Jaschinski, Philipp Täger, Verena Marmann, Melanie von Brandenstein, Barbara Köditz, Thomas Fischer, Sergio Muñoz-Vázquez, Beate Zimmermanns, Markus Dietlein, Ferdinand Sudbrock, Phillip Krapf, Dietmar Fischer, Axel Heidenreich, Alexander Drzezga, Stefan Kirsch, Markus Pietsch, Klaus Schomäcker
Publikováno v:
Organic & Biomolecular Chemistry. 21:3090-3095
We identified a new estrogen receptor (ER)-targeting ligand with picomolar affinity serving as vehicle for radioiodines. This ligand is a potential radiotheranostics for ER+ male tumours.
Autor:
Simone Wegen, Katrin Sabine Roth, Jasmin Weindler, Karina Claus, Philipp Linde, Maike Trommer, Dennis Akuamoa-Boateng, Lutz van Heek, Christian Baues, Birgid Schömig-Markiefka, Klaus Schomäcker, Thomas Fischer, Alexander Drzezga, Carsten Kobe, Christhardt Köhler, Simone Marnitz
Publikováno v:
Clinical nuclear medicine 48(2), 150-155 (2023). doi:10.1097/RLU.0000000000004505
In several solid tumors, fibroblast activation protein (FAP) is overexpressed by cancer-associated fibroblasts in the tumor microenvironment. Preliminary evidence suggests that detection and staging are feasible with PET/CT imaging using [68Ga]-radio
Publikováno v:
Organic & Biomolecular Chemistry. 19:9849-9854
In this work, we describe the synthesis, in vitro stability, and preliminary biological evaluation of [177Lu]Lu–DOTA–p160 peptide-based radiopharmaceuticals. Our findings highlight that all DOTA–p160–peptide radioconjugates exhibit favorable
Autor:
Simone, Wegen, Lutz, van Heek, Philipp, Linde, Karina, Claus, Dennis, Akuamoa-Boateng, Christian, Baues, Shachi Jenny, Sharma, Klaus, Schomäcker, Thomas, Fischer, Katrin Sabine, Roth, Jens Peter, Klußmann, Simone, Marnitz, Alexander, Drzezga, Carsten, Kobe
Publikováno v:
Molecular imaging and biology. 24(6)
In head and neck cancers (HNCs), fibroblast activation protein (FAP) is expressed by cancer-associated fibroblasts (CAFs) in the tumor microenvironment. Preliminary evidence suggests that detection and staging is feasible with positron emission tomog